Subtype
Malignant Hepatobiliary Neoplasm
CI-CAN-00001136Explore in graph →
1,160 active trials17 approved drugs42 evidence items
- NCIt
- C8609
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001136Explore in graph →
Clinical trials
5,029 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (561)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05823584 | Cell-free DNA From Junction of Hepatitis B Virus Integration in HCC Patients for Monitoring Post-resection Recurrence | completed | — | 207 | TCM Biotech International Corp.INDUSTRY | 1 | Apr 10, 2024 | clinicaltrials |
| NCT03201458 | Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer | completed | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2024 |
| clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06313047 | Pharmacogenetic of Doxorubicin in HCC. | completed | — | 81 | Rehab WeridaOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT04059562 | Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma(TRITICC) | completed | Phase 2 | 28 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT02273362 | Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver | completed | Phase 1 / Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06190574 | Diagnostic Efficacy and Prognostic Value of 18F-FDG PET/CT (MR) in Pediatric Solid Blastoma | completed | — | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT06315101 | Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China | completed | — | 142 | Guangzhou University of Chinese MedicineOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT03339843 | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib(MiMe-A) | completed | Phase 2 | 85 | Jules Bordet InstituteOTHER | 2 | Mar 15, 2024 | clinicaltrials |
| NCT04451603 | LiverMultiScan Analysis of MRI Scans in HCC | completed | — | 21 | National Cancer Centre, SingaporeOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT05239507 | OREIOS International Study(OREIOS) | completed | — | 1,127 | AstraZenecaINDUSTRY | 11 | Mar 13, 2024 | clinicaltrials |
| NCT06030895 | Sorafenib In Egyptian Patients With Hepatocellular Carcinoma. | completed | N/A | 100 | Damanhour UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06298123 | Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling | completed | — | 304 | Chen XiaopingOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT04618367 | HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT | completed | N/A | 30 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04627012 | Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma | completed | — | 600 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT02182687 | Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant(SBRTvsTACE) | completed | Phase 2 | 60 | Lahey ClinicOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT00019630 | Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT04103398 | TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma(TREAT) | completed | Phase 3 | 162 | Sun Yat-sen UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06041425 | The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE | completed | Phase 4 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT01505569 | Auto Transplant for High Risk or Relapsed Solid or CNS Tumors | completed | N/A | 44 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT02859753 | Comparison of Response and Recurrence Rates Following Percutaneous Microwave Coagulation Therapy Versus Percutaneous Radiofrequency Ablation(Thermoablation) | completed | N/A | 35 | Centre Hospitalier Universitaire DijonOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT03047603 | Evaluation of Diagnostic Efficiency of PIVKA-II and Other Tumor Markers in HCC | completed | — | 4,005 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06265883 | Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT | completed | — | 205 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06261138 | Survival Analysis: TACE vs. Combination Therapy in HCC | completed | — | 279 | Zhejiang UniversityOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT06258824 | MicroRNAs as Bile-based Biomarkers in Pancreaticobiliary Cancers(MIRABILE) | completed | — | 229 | Imperial College LondonOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT02168140 | CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | completed | Phase 1 | 16 | Wake Forest University Health SciencesOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT03893695 | Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) | completed | Phase 1 / Phase 2 | 20 | Suzhou Kintor Pharmaceutical Inc,INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT06245798 | Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension | completed | — | 3,000 | Tang-Du HospitalOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT02695628 | [18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer | completed | Phase 2 | 5 | Stanford UniversityOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06233708 | Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant | completed | — | 2,092 | Asan Medical CenterOTHER | 0 | Jan 31, 2024 | clinicaltrials |
| NCT04720131 | Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer. | completed | Phase 2 | 28 | Beijing Friendship HospitalOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06199297 | Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma | completed | — | 188 | Sun Yat-sen UniversityOTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT06222619 | Effect of PVE on Surgical Outcomes and Long-term Survival in Perihilar Cholangiocarcinoma | completed | — | 136 | Seoul National University HospitalOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT02649153 | Effect of Smoked Plum and Chewing Gum on Postoperative Bowel Function Following Hepatic Resection(SP/GC-HCC) | completed | Phase 3 | 240 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT02650271 | Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC | completed | Phase 3 | 240 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT02329860 | Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP) | completed | Phase 3 | 400 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 22, 2024 | clinicaltrials |
| NCT03535259 | Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma(SIRAHCC) | completed | Phase 2 | 86 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT00486356 | Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer | completed | Phase 1 | 46 | University of NebraskaOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT01004978 | Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | completed | Phase 3 | 235 | National Cancer Institute (NCI)NIH | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06189664 | Evaluation of the Effectiveness of Intraoperative Frozen Section on the Treatment of Suspected Gallbladder Cancer | completed | — | 37 | Imperial College LondonOTHER | 0 | Jan 3, 2024 | clinicaltrials |
| NCT01825603 | ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer | completed | Phase 1 | 17 | University of NebraskaOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT03219268 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | completed | Phase 1 | 277 | MacroGenicsINDUSTRY | 8 | Dec 21, 2023 | clinicaltrials |
| NCT03230318 | Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma(FIDES-01) | completed | Phase 2 | 148 | Basilea PharmaceuticaINDUSTRY | 11 | Dec 19, 2023 | clinicaltrials |
| NCT00683631 | TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)(TheraSphere) | completed | — | 183 | University of LouisvilleOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT01624285 | Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer | completed | Phase 2 | 20 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT02561273 | Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 54 | University of NebraskaOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT03006926 | A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma | completed | Phase 1 | 104 | Eisai Co., Ltd.INDUSTRY | 7 | Dec 13, 2023 | clinicaltrials |
| NCT05007548 | to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography Volumetry and Indocyanine Green Retention Test for Measurement of Liver Reserve | completed | Phase 2 | 30 | National Atomic Research Institute, TaiwanOTHER | 1 | Dec 13, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 10, 2024source: clinicaltrials